Two Sigma Advisers
KPRX icon

Two Sigma Advisers’s Kiora Pharmaceuticals KPRX Stock Holding History

Two Sigma Advisers’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-106
Closed -$139K – 2568
2021
Q2 		$139K Sell
106
-74
-41% -$115K ﹤0.01% 2318
2021
Q1 		$323K Buy
+180
New +$392K ﹤0.01% 2193

Other funds holding KPRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $60.8M AUM 17.47% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Two Sigma Advisers's KPRX Position: Q3 2021 in Review

Two Sigma Advisers sold out of Kiora Pharmaceuticals (KPRX) in Q3 2021, closing a stake of 106 shares — an estimated $139K sold.

Two Sigma Advisers first reported a position in KPRX in Q1 2021 and held it in 2 quarters. The position peaked at $323K in Q1 2021. 19 funds tracked by Wall St. Rank hold KPRX as of Q3 2021.

  • Two Sigma Advisers reported no remaining Kiora Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 106 Kiora Pharmaceuticals shares in Q3 2021, an estimated $139K.
  • Two Sigma Advisers first reported a position in Kiora Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Kiora Pharmaceuticals position peaked at $323K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2021.

Based on Two Sigma Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.